Both this novel therapeutic and Semaglutide represent notable advancements in obesity treatment , but they function through distinct mechanisms. Semaglutide primarily affects GLP-1 receptors, enhancing insulin release and curbing appetite. conversely is a dual-agonist, impacting both GLP-1 and GI

This report offers a detailed overview of Tirzepatide, a novel medication employed for addressing weight and related problems. Initially cleared for treating type 2 diabetes, Tirzepatide shown significant results in supporting a decrease in weight in individuals who struggle with obesity. We will